EUVIMEDDescoperă EUVIMED
Crossref

Les antagonistes de la cholécystokinine: futurs antalgiques?

C. Mann

Douleur et Analgésie · 1997

DOI: 10.1007/bf03003146 ↗

At a glance

Journal article in Douleur et Analgésie, 1997. Written by C. Mann. Cited 1 times so far (Crossref); 22 references.

RezumatDate bibliograficeCiteRelated studies

Abstract (original language)

Cholecystokinin (CCK) is located in the brain and the spinal cord. CCK acts as a neuromediator and produces various biological effects that are mediated by two receptors: CCK-A and CCK-B, the predominant form found in the central nervous system. Electrophysiological and behavioural studies suggest the existence of regulatory mechanism between CCK and opioid systems in the control of pain. Thus, it has been proposed that CCK could act as an endogenous opiate and play a role in the development of morphine tolerance. In contrast, administration of a CCK-B receptor antagonist may enhance the antinociceptive effect of morphine. Experimental and clinical studies indicate the possibility for the therapeutic use of selective and specific CCK-B receptor antagonists as co-analgesics with morphine in postoperative period or in patient with intractable pain.

Cite

APA

Mann, C. (1997). Les antagonistes de la cholécystokinine: futurs antalgiques?. Douleur et Analgésie. https://doi.org/10.1007/bf03003146

Vancouver

Mann C. Les antagonistes de la cholécystokinine: futurs antalgiques?. Douleur et Analgésie. 1997. doi:10.1007/bf03003146

BibTeX
@article{Mann1997,
  author = {Mann, C.},
  title = {Les antagonistes de la cholécystokinine: futurs antalgiques?},
  journal = {Douleur et Analgésie},
  year = {1997},
  doi = {10.1007/bf03003146}
}
Start for free →